Study of Hormone Therapy Before Surgery to Improve Outcomes in Women Over 50 With Invasive Lobular Breast Cancer

What this Trial Is About

Researchers are evaluating how well neoadjuvant endocrine therapy NET works for postmenopausal women aged 50 years and older with invasive lobular carcinoma ILC of the breast. The study focuses on women with the ERHER2- subtype who plan to have breast-conserving surgery BCS. The main goal is to determine if NET reduces the chance of cancer cells being found at the edges of tissue removed during surgery, which is known as positive surgical margins. Participants will receive neoadjuvant endocrine therapy using drugs such as anastrozole, letrozole, exemestane, or tamoxifen before surgery. The treatment is given before the planned breast-conserving surgery. The study is a phase 2 trial and includes women with biopsy-confirmed tumors classified as stage cT2-T3 N0-1. During the study, participants will be monitored for up to 3 months to assess the rate of positive surgical margins after their breast cancer surgery. Researchers will review surgical outcomes and safety data. The study team will also evaluate how the endocrine therapy affects surgical success and patient health during this period. The total participation time includes treatment before surgery and follow-up assessments afterward to measure surgical results.

A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer